Mar. 20 at 3:44 PM
$COSM This release raises serious governance questions.
“Using non-core assets to fund acquisitions” requires full transparency — particularly around valuation and any potential related-party involvement.
Shareholders need clarity on:
• what assets may be sold,
• how they will be valued,
• and whether any acquisitions involve affiliated entities.
There are also outstanding questions regarding Docpharm. Based on prior disclosures, significant capital has been directed toward that entity. Shareholders need clarity on ownership. At a minimum, investors should understand why assets supported by Cosmos (like DocPharm) are not already FULLY consolidated at the Cosmos level.
Importantly, the role of the Board is critical here. The Board is responsible for ensuring that capital allocation decisions are made independently, transparently, and in the best interest of all shareholders.
Governance, alignment, and disciplined execution — not just announcements — will determine credibility.
